Representative Josh Gottheimer (D-New Jersey) recently bought shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on April 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on March 7th. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.
Representative Josh Gottheimer also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Spotify Technology NYSE: SPOT on 3/24/2025.
- Sold $1,001 - $15,000 in shares of Flywire NASDAQ: FLYW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Disco OTCMKTS: DSCSY on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Shopify NYSE: SHOP on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk NYSE: TLK on 3/19/2025.
- Sold $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 3/19/2025.
- Sold $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 3/19/2025.
Gilead Sciences Stock Up 0.2 %
NASDAQ GILD traded up $0.21 during mid-day trading on Wednesday, reaching $105.89. The stock had a trading volume of 1,750,350 shares, compared to its average volume of 7,473,537. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a fifty day moving average price of $108.63 and a 200 day moving average price of $97.11. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $131.85 billion, a PE ratio of 286.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.
Insiders Place Their Bets
In related news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 300,285 shares of company stock worth $30,274,875 in the last ninety days. 0.16% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on GILD shares. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Oppenheimer increased their price target on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Finally, Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $105.12.
Check Out Our Latest Stock Analysis on Gilead Sciences
Hedge Funds Weigh In On Gilead Sciences
Hedge funds have recently bought and sold shares of the company. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company's stock.
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
